Candel Therapeutics, Inc. filings document a clinical-stage oncology company developing multimodal biological immunotherapies and reporting as a Nasdaq-listed issuer of common stock. Its proxy materials cover director elections, auditor ratification and annual-meeting voting matters, while Form 8-K reports furnish operating and financial results and research-and-development presentations.
Other filings disclose material agreements and capital-structure matters, including term-loan financing and facility lease amendments, along with clinical and regulatory disclosures tied to aglatimagene besadenovec and linoserpaturev. The filing record also reflects governance matters, shareholder voting mechanics and exhibit-based disclosures for key corporate actions.
Candel Therapeutics is calling a virtual 2026 annual stockholder meeting on June 23, 2026 at 10:00 a.m. Eastern via www.virtualshareholdermeeting.com/CADL2026. Stockholders will elect four Class II directors to serve until 2029 and vote on ratifying KPMG LLP as independent auditor for 2026.
Holders of 73,270,239 shares of common stock as of April 24, 2026 may vote online, by phone, mail or during the webcast. The company uses SEC “Notice and Access” to distribute materials electronically and remains an emerging growth and smaller reporting company, providing scaled governance and executive compensation disclosure.
BlackRock, Inc. amends a Schedule 13G to report beneficial ownership of CANDEL THERAPEUTICS INC common stock. The amendment shows 3,079,861 shares beneficially owned, equal to 4.2% of the class; BlackRock reports sole voting power for 3,042,067 shares and sole dispositive power for 3,079,861 shares. The filing is signed by Spencer Fleming on 04/27/2026.
Candel Therapeutics director Paul B. Manning received a stock option grant covering 4,618 shares of Common Stock. The options have an exercise price of $4.90 per share, were fully vested at the time of grant, and expire on March 31, 2036. According to the filing, this award was given in lieu of normal quarterly cash payments, and following the grant he holds options for 4,618 shares directly.
Candel Therapeutics director Joseph C. Papa received a grant of 2,795 stock options as compensation. The options were awarded on March 31, 2026 with an exercise price of $4.90 per share and relate to 2,795 shares of common stock.
This award was granted in lieu of normal quarterly cash payments and is fully vested at the time of grant. Following this grant, Papa holds 2,795 derivative securities directly, and the options are scheduled to expire on March 31, 2036.
Candel Therapeutics director Nicoletta Loggia received a fully vested stock option award covering 779 shares of common stock. The option has an exercise price of $4.90 per share and was granted in lieu of normal quarterly cash payments, leaving her with 779 derivative securities following the grant.
Paul B. Manning and affiliated entities filed an amended Schedule 13D reporting beneficial ownership of 5,790,999 shares of Candel Therapeutics common stock, equal to 7.9% of the outstanding shares. The holdings are spread across Paul and Diane Manning jointly, The Paul B. Manning Revocable Trust, BKB Growth Investments, LLC, and stock options.
As of the filing, Paul and Diane Manning jointly hold 1,681,000 shares, the Trust holds 2,763,527 shares, BKB holds 1,303,752 shares, and 42,720 shares are issuable upon option exercise within 60 days of February 26, 2026. The ownership percentages are based on 73,244,473 shares outstanding as of February 20, 2026.
The amendment also records that on February 23, 2026, the Trust purchased 550,458 shares in an underwritten offering at $5.45 per share for $3 million, adding to earlier investments made through preferred financing, the IPO, open-market purchases, and prior offerings.
Candel Therapeutics, Inc. reports its annual update as a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies for solid tumors. Its lead adenoviral candidate, aglatimagene besadenovec, showed a statistically significant disease-free survival benefit in a 745‑patient phase 3 trial in intermediate‑ and high‑risk localized prostate cancer (hazard ratio 0.70; p=0.0155), received RMAT and Fast Track designations, and is being prepared for a planned Biologics License Application submission in the fourth quarter of 2026.
The company is also advancing aglatimagene in non-small cell lung cancer, where a phase 2a trial in patients progressing on checkpoint inhibitors reported median overall survival up to 25.4 months in non-squamous disease versus 9.8–11.8 months in published chemotherapy data. A pancreatic cancer study showed prolonged survival but further work is paused pending external funding. Candel’s HSV-based candidate, linoserpaturev, has produced encouraging survival and immune-activation signals in recurrent high‑grade glioma, supported by Fast Track and Orphan Drug designations, with multiple-dose data and enabling work for a future randomized phase 2 underway. The company also highlights its enLIGHTEN™ Discovery Platform for next‑generation viral immunotherapies, while noting it has no product revenue, expects continuing losses, relies on external manufacturing, and must raise substantial additional capital.
Candel Therapeutics reported fourth quarter and full year 2025 results and outlined key clinical and financing milestones. Research and development expenses rose to $30.5M in 2025 from $19.3M in 2024, while general and administrative expenses increased to $17.8M from $14.1M. Net loss narrowed to $38.2M in 2025 from $55.2M in 2024, helped by $10.1M of net other income, mainly from warrant liability revaluation. Cash and cash equivalents were $119.7M as of December 31, 2025, compared with $102.7M a year earlier.
The company completed a February 2026 follow-on equity offering that generated $93.5M in net proceeds and entered a $130M term loan facility, drawing $50M at closing. Based on these resources, Candel expects to fund its operating plan into Q1 2028. The plan includes a planned pivotal phase 3 trial of aglatimagene besadenovec in non-small cell lung cancer, a planned BLA submission for aglatimagene in localized intermediate- to high-risk prostate cancer in Q4 2026, and continued development of linoserpaturev in recurrent high-grade glioma.
Candel Therapeutics director Paul B. Manning, through The Paul B. Manning Revocable Trust, completed an open-market purchase of 550,458 shares of common stock at $5.45 per share. After this transaction, indirect holdings include shares in the Trust and in BKB Growth Investments, LLC, plus additional shares held directly and jointly with his spouse.